- Home
- NKTR vs HLXB Comparison
NKTR vs HLXB Comparison
Compare NKTR & HLXB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKTR
- HLXB
- Stock Information
- Founded
- NKTR 1990
- HLXB 2021
- Country
- NKTR United States
- HLXB United States
- Employees
- NKTR N/A
- HLXB N/A
- Industry
- NKTR Biotechnology: Pharmaceutical Preparations
- HLXB
- Sector
- NKTR Health Care
- HLXB
- Exchange
- NKTR Nasdaq
- HLXB NYSE
- Market Cap
- NKTR 238.7M
- HLXB 244.6M
- IPO Year
- NKTR 1994
- HLXB 2024
- Fundamental
- Price
- NKTR $1.36
- HLXB $10.50
- Analyst Decision
- NKTR Buy
- HLXB
- Analyst Count
- NKTR 4
- HLXB 0
- Target Price
- NKTR $2.50
- HLXB N/A
- AVG Volume (30 Days)
- NKTR 1.0M
- HLXB 14.1K
- Earning Date
- NKTR 11-05-2024
- HLXB 01-01-0001
- Dividend Yield
- NKTR N/A
- HLXB N/A
- EPS Growth
- NKTR N/A
- HLXB N/A
- EPS
- NKTR N/A
- HLXB N/A
- Revenue
- NKTR $93,157,000.00
- HLXB N/A
- Revenue This Year
- NKTR N/A
- HLXB N/A
- Revenue Next Year
- NKTR N/A
- HLXB N/A
- P/E Ratio
- NKTR N/A
- HLXB N/A
- Revenue Growth
- NKTR 6.17
- HLXB N/A
- 52 Week Low
- NKTR $0.41
- HLXB $10.03
- 52 Week High
- NKTR $1.93
- HLXB $10.83
- Technical
- Relative Strength Index (RSI)
- NKTR 59.09
- HLXB N/A
- Support Level
- NKTR $1.24
- HLXB N/A
- Resistance Level
- NKTR $1.42
- HLXB N/A
- Average True Range (ATR)
- NKTR 0.09
- HLXB 0.00
- MACD
- NKTR 0.01
- HLXB 0.00
- Stochastic Oscillator
- NKTR 80.65
- HLXB 0.00
About NKTR Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
About HLXB HELIX ACQUISITION CORP. II
Helix Acquisition Corp II is a Blank check company.